|Project Title||Principal Investigator||Institution|
|Validation study of atypical dynamic pupillary light reflex as a biomarker for autism||Yao, Gang; Miles, Judith; Christ, Shawn||University of Missouri|
|Temperament, emotional expression, and emotional self-regulation in relation to later ASD diagnosis||Wozniak, Robert||Bryn Mawr College|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype||White, Keith||University of Florida|
|Neurophysiological indices of risk and outcome in autism||Webb, Sara||University of Washington|
|Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism||Vogt, Robert||Centers for Disease Control and Prevention (CDC)|
|Neurobehavioral research on infants at risk for SLI and autism||Tager-Flusberg, Helen; Nelson, Charles||Boston University Medical Campus|
|Family/Genetic study of autism||Smith, Christopher||Southwestern Autism Research & Resource Center (SARRC)|
|Neurophysiological investigation of language acquisition in infants at risk for ASD||Seery, Anne||Boston University|
|ACE Center: Integrated Biostatistical and Bioinformatic Analysis Core (IBBAC)||Schork, Nicholas||University of California, San Diego|
|Placental vascular tree as biomarker of autism/ASD risk||Salafia, Carolyn||Research Foundation for Mental Hygiene, Inc.|
|Supplement to NIH ACE Network grant: "A longitudinal MRI study of infants at risk for autism"||Piven, Joseph||University of North Carolina at Chapel Hill|
|ACE Network: A longitudinal MRI study of infants at risk for autism||Piven, Joseph||University of North Carolina at Chapel Hill|
|ACE Center: Clinical Phenotype: Recruitment and Assessment Core||Pierce, Karen||University of California, San Diego|
|Studying the biology and behavior of autism at 1-year: The Well-Baby Check-Up approach||Pierce, Karen||University of California, San Diego|
|Temporal coordination of social communicative behaviors in infant siblings of children with autism||Parlade, Meaghan||University of Pittsburgh|
|Oxytocin biology and the social deficits of autism spectrum disorders||Parker, Karen||Stanford University|
|Infants at risk of autism: A longitudinal study||Ozonoff, Sally||University of California, Davis|
|Electrophysiological, metabolic and behavioral markers of infants at risk||Nelson, Charles||Children's Hospital Boston|
|RNA expression studies in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|Signatures of gene expression in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|ACE Center: Linguistic and social responses to speech in infants at risk for autism||Kuhl, Patricia||University of Washington|
|Model diagnostic lab for infants at risk for autism||Klin, Ami||Yale University|
|Brain-behavior growth charts of altered social engagement in ASD infants||Klin, Ami||Yale University|
|Physical and clinical infrastructure for research on infants-at-risk for autism at Yale||Klin, Ami||Yale University|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.